Histone hypo-acetylation of Sox9 mediates nicotine-induced weak cartilage repair by suppressing BMSC chondrogenic differentiation

Kai Tie 1, Min Wu 1,4, Yu Deng 1,4, Yinxian Wen 1,4, Dan Xu 2,4, Liaobin Chen 1* and Hui Wang 2,4*

Abstract

Background: Nicotine has negative effects on tissue repair, little research concerns its effect on the cartilage repair of tissue engineering stem cells. The present study aimed to investigate the effects of nicotine on the bone marrow-derived mesenchymal stem cells' (BMSCs) chondrogenic repair function of cartilage defects and explored the molecular mechanism.

Methods: A cartilage defect model of rat was repaired by BMSC transplantation, and treated with nicotine or saline at 2.0 mg/kg/d in 12 weeks. Nicotine's effect on chondrogenic differentiation was studied by exposing BMSCs to nicotine at 0.1, 1, 10, and 100 μM, and methyllycaconitine (MLA), which is a selective α7-nicotinic acetylcholine receptor (nAChR) inhibitor and si-RNA of nuclear factor of activated T cells 2 (NFATc2), were used to verify the molecular mechanism of nicotine's effect.

Results: Data showed that nicotine inhibited cartilage repair function by suppressing SRY-type high-mobility group box 9 (Sox9) in regenerated tissues. Further in vitro study demonstrated that nicotine enhanced intracellular Ca2+ and activity of calcineurin (CaN) through α7-nAChR, increased the nucleic expressions of NFATc2 and the bindings to SOX9 promoter, and thus reduced the acetylation of H3K9 and H3K14 in SOX9 promoter.

Conclusions: Findings from this study demonstrated that nicotine suppressed the chondrogenic differentiation of BMSCs in vivo and in vitro, which offers insight into the risk assessment of cartilage defect repair in a nicotine exposure population and its therapeutic target.

Keywords: Nicotine, Bone marrow-derived mesenchymal stem cells, Chondrogenic differentiation, Cartilage defect, Histone acetylation

Background

Articular cartilage is composed of chondrocytes and extracellular matrix, which primarily consists of collagen II and proteoglycans [1]. It covers the metaphysis of long bones and provides shock absorption and lubrication to diarthrodial joints. Cartilage tissue has poor self-healing capacity because it is avascular and thus has inadequate access to progenitor cells from blood and bone marrow (BM), which facilitate regeneration [2]. The articular cartilage defect is accompanied by pain and loss of function, and progressive breakdown leads to degenerative disorders, such as osteoarthritis, which can seriously affect a patient's life and work. Epidemiological studies had indicated that cartilage defects were found in 60% of patients who underwent arthroscopic surgery and that the main population included young adults [3]. Therefore, the optional repair and regeneration of cartilage defect is an important issue in medical research.

Mesenchymal stem cells (MSCs) can be isolated from various tissues and can differentiate into chondrogenic lineage cells in vitro and in vivo [4, 5]. In 2002, Wakitani...
et al. [6] applied bone marrow mesenchymal stem cell (BMSC) transplants to repair human articular cartilage defects in osteoarthritic knee joints and observed that the cartilage defects were partially covered with hyaline cartilage-like tissue, which highlighted the availability of autologous culture-expanded BMSC transplantation for the repair of articular cartilage defects in humans. Since then, numerous studies on using BMSCs to repair cartilage lesions, from preclinical findings to clinical application, have been performed as BMSCs can be easily obtained and used [7]. The transplantation of BMSCs has become one of the main methods for treating cartilage defects [8–10]. However, the mechanism focused on how to optimize the microenvironment or improve the efficiency of chondrogenic differentiation of BMSCs, and there was no concern about adverse factors in the differentiation process.

As a key component of smoking, nicotine has negative effects on tissue repair and healing [11, 12]. An epidemiological study had demonstrated that nicotine abuse was a high-risk factor that influences the clinical outcome of cartilage defects repair of the knee [13]. Our previous study indicated that prenatal nicotine exposure induced fetal articular dyschondroplasia [14]. The epiphyseal cartilage development is a process of proliferation and differentiation of MSCs [15], in which nicotine can interfere with the chondrogenic differentiation of MSCs in vivo. The process of repairing cartilage defects is also a process of chondrogenic differentiation of stem cells [16]; therefore, nicotine may have an adverse effect on the chondrogenic repair of BMSCs in cartilage defects.

Our previous work has demonstrated that nicotine could suppress the chondrogenic differentiation potential of BMSCs and result in poorly differentiated cartilage [17]. However, the mechanism is still unclear. SRY-type high mobility group box 9 (Sox9) is a key regulator and controls the expression of the α1 chain of type II collagen (Col2A1) gene in the initiation stage of MSC chondrogenic differentiation [18]. During primary chondrogenesis, which is activated by transforming growth factor beta (TGF-β), Sox9 binds to essential sequences in the Col2A1 gene enhancers and initiates its expression [19]. The functional modulation of Sox9 is a critical step for the initiation of chondrogenesis and is mainly regulated by histone acetylation [20]. The nuclear factor of activated T cells (NFAT) transcription factor NFATc2 (NFATc2) is a repressor of chondrogenesis [21] and can interact with histone deacetylase (HDAC) proteins to induce gene silencing [22]. Calcineurin (CaN), an upstream molecule of NFATc2, is induced by increased Ca²⁺ and can translocate the dephosphorylated NFATc2 into the nucleus [23]. The stimulus of nicotine can increase the intracellular Ca²⁺ of MSCs through nicotinic acetylcholine receptor (nAChR) [24]. Therefore, we hypothesized that nicotine could decrease Sox9’s promoter histone acetylation and inhibit its expression through HDAC recruitment by the activated nAChR/Ca²⁺/calcineurin/NFAT pathway in BMSCs.

In this study, we confirmed that nicotine interfered with BMSC transplantation repair of cartilage defects by inhibiting Sox9 expression in vivo and that nicotine-induced Sox9 gene suppression via nAChRs is mediated directly by decreasing the histone acetylation of the Sox9 promoter.

**Methods**

**Animal studies**

Animal experiments in this study were approved by the Committee on the Ethics of Animal Experiments of the Wuhan University School of Medicine (No. 14016). The animal experimental procedures were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals (eighth edition) from the National Research Council of the United States National Academies, and performed in the Center for Animal Experiment of Wuhan University (Wuhan, China), which was accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International). Female (weighing 180–220 g) and male (weighing 260–300 g) Wistar rats at 12 weeks old were obtained from the Experimental Center of the Medical Scientific Academy of Hubei (no. 2008–0005). Rats were housed in metal cages with wire-mesh floors in an air-conditioned room under standard conditions (room temperature: 18–22 °C; humidity: 40–60%; light cycle: 12 h light-dark cycle; 10–15 air changes per hour) and allowed free access to rat chow and tap water.

Rats were randomly distributed into control (BMSCs) and experimental (BMSCs + nicotine) groups (n = 8 for each group). The cartilage defect model in the two groups followed the method described by Chung et al. [25]. In brief, anesthesia was performed with an intraperitoneal injection of 3.5 ml/kg of 10% chloral hydrate. In each case, after cleaning with 10% betadine solution, right knee joints of each rat were sterilely draped, and experimental (BMSCs + nicotine) groups were laterally dislocated, and full-thickness articular cartilage defects (2 mm in diameter) were created in trochlear grooves by carefully drilling in a vertical direction using a 2-mm drill. Drilling was performed in 3 mm deep through subchondral bone. After removing cartilage and bone debris, boundaries around the drill were trimmed using a surgical knife and washed out. The mixture containing BMSCs (2 × 10⁶ cells/ml) and 1.25% alginate in 0.15 M saline [26] was then transplanted into the full-thickness defect in the right knee. Following implantation, patellar retinaculum and overlying soft tissues were closed in layers. Rats were allowed to move...
knee joints freely in their cages without restriction. An intraperitoneal injection of $4 \times 10^5$ U of penicillin (Harbin Pharmaceutical Group, Shanghai, China) was administered immediately after implantation and once daily for 1 week. Clinical signs were observed daily during the study period. Animals were sacrificed at 12 weeks post-implantation to assess cartilage repair statuses. The experimental group was injected with nicotine (Sigma-Aldrich, St Louis, MO, USA) at 1.0 mg/kg twice per day (2.0 mg/kg/d).

As a preliminary study, defects of the same size (2 mm diameter and 3 mm deep) were created, and the cartilage repair with no treatment or alginate only was observed. At 12 weeks post-transplantation, the defects showed very poor cartilage repair (Additional file 1), whose surface was concave, irregular or sometimes empty in the middle and few regenerated tissues could be seen in peripheral regions, meaning that this size of articular cartilage defect in a rat joint is a critical-size defect that cannot heal by itself. Therefore, a defect only without BMSC transplantation (no treatment or alginate only) was not included in the present study.

**Gross and histological evaluations**

Rats were sacrificed by cervical dislocation with an intraperitoneal injection of 3.5 ml/kg of 10% chloral hydrate. The entire right knee was dissected, and a distal part of the femur was then extirpated. The samples from each group were examined and photographed to evaluate the degree of defect repair (0–4), integration to border zone (0–4), and macroscopic appearance (0–4) according to the International Cartilage Repair Society (ICRS) macroscopic assessment scale for cartilage repair [27].

After gross examination, samples were fixed in 4% paraformaldehyde, decalcified in 20% ethylenediaminetetraacetic acid (EDTA) (pH 7.4) for 21 d, and embedded in paraffin. Serial 5-mm thick sections were cut in a horizontal plane across the joint. Two sections within every consecutive ten sections were stained with Safranin-O/Fast green (Sigma-Aldrich) and the one with better morphology was used for quantification. The cartilage repair was scored by two blinded authors (K.T. and Y.D.) using a method described by Wakitani [28]. In brief, each section was assigned a score, which was the sum of cell morphology (0–4), matrix-staining (0–3), surface regularity (0–3), thickness of cartilage (0–3), and integration of donor with host (0–3). The expression of Col2A1 and Sox9 in the regenerated tissue was analyzed by immunohistological staining. After antigen retrieval by boiling the samples in sodium citrate buffer, the sections were blocked in serum for 30 min, followed by incubation with the primary antibody in a humidified chamber at 4 °C overnight. A biotinylated secondary antibody was added for 30 min on day 2, followed by an avidin-biotinlated horseradish peroxidase complex, according to the manufacturer’s directions. Finally, the peroxidase activity was revealed by immersion in DAB substrate. The following primary antibodies were used: rabbit anti-Sox9, and rabbit anti-Col2A1 (both from Santa Cruz Biotechnology, Dallas, TX, USA). To characterize the changes in immunostaining, the mean optical densities (MODs) were obtained from ten areas of regenerated tissue from five separate samples.

**Culture of BMSCs and chondrogenic differentiation of BMSCs**

The isolation and culture of rat BMSCs from the tibias and femurs of 4-week-old Wistar rats were performed as described previously [17]. Briefly, the rats were sacrificed by cervical dislocation after anesthesia (intraperitoneal injection of 10% chloral hydrate) and sterilized using 75% ethanol for 10 min before surgery. After dissecting the metaphyseal ends of the bones under sterile conditions, the bone marrow cells were flushed out using Dulbecco’s modified Eagle’s medium (DMEM/F12 medium supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA), 50 mg/ml of L-ascorbic acid (Sigma-Aldrich), 1% glutamine (Sigma-Aldrich), 100 mg/ml of streptomycin and penicillin (Sigma-Aldrich), and centrifuged at 1000 rpm for 5 min. The cells were resuspended and expanded in T-25 flasks (Cyagen Biosciences, Santa Clara, CA, USA) with DMEM/F12 medium and incubated at 37 °C under conditions of 5% CO₂. The medium was changed every 3 days. Upon reaching 70%–80% confluence, adherent cells were trypsinized, harvested, and expanded. Cells that had undergone three passages were used in subsequent experiments.

Chondrogenic differentiation of BMSCs was performed following the method described in our previous work [17]. Monolayer culture cells in T-25 flasks were trypsinized, washed, and centrifuged. The isolated BMSCs were suspended at a concentration of $6 \times 10^6$ cells/ml in a 1.25% alginate (Sigma-Aldrich) in 0.15 M NaCl, and then the cell suspension was slowly dropped into a 102 mM CaCl₂ solution. The beads were cultured in six-well plates under conditions of 5% O₂ with DMEM/F12 medium containing 1% insulin, transferrin and selenous (ITS) (Sigma-Aldrich), 100 nM dexamethasone (Sigma-Aldrich) and 10 ng/ml transforming growth factor-β1 (TGF-β1) (PeproTech Rocky Hill, NJ, USA). During the period of chondrogenic differentiation, the culture medium with or without nicotine at concentrations of 0.1, 1.1, 10, and 100μM was replaced every other day. The BMSCs treated with nicotine for 24 h were used in the experiments for molecular mechanism detection.
RNA interference
siRNAs for NFATc2 (L-011778) were purchased from Gene Pharma (Shanghai Gene Pharma Co.). The scramble-sense siRNA targeted the sequence 5'-GGAA GCUCACGUGGAUAAATT-3', and the scramble-antisense siRNA targeted the sequence 5'-UUUAUCCACU GUAGCCUCCCTT-3'. In brief, passage 3 BMSCs were plated to obtain 70–80% confluence in six-well plates and transfected with si-NFATc2 using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), negative control siRNA or Lipofectamine 2000 only. After 6 h of transfection, fresh medium was exchanged. The expression of NFATc2 was detected using RT-qPCR and Western blotting.

Calcium imaging and phosphatase activity of calcineurin
P3 BMSC cultures in 35 mm glass-bottomed plates were prepared. The cells were washed using Hank’s solution three times and incubated in dye loading solution containing 1μM Fluo-3 AM (DoJinDo, Shanghai, China) at 37 °C for 30 min and then at room temperature for an additional 30 min. Before nicotine stimulation, PBS buffer was used to wash the cells three times. The fluorescence was measured after the addition of 0.1, 1, 10, and 100 μM nicotine. Measurements were performed in a laser scanning confocal microscope (Carl Zeiss, Oberkochen, Germany) by collecting data points every 5 s over 20 min using LCS Lite confocal software.

The phosphatase activity of calcineurin was measured using a calcineurin assay kit (A068, Nanjing Jiancheng Bioengineering Institute, Nanjing, China). In short, the protein of BMSCs was extracted and quantified, the enzymatic reaction was initiated using calmodulin and p-nitrophenyl phosphate (PNPP) as a substrate, and then the inorganic phosphorus content was measured. The enzyme activity unit of calcineurin was defined as the amount of 1 M inorganic phosphorus produced by decomposing 1 mg calcineurin from the substrate PNPP per hour, and the results were expressed as U/mg protein.

Western blotting
To obtain total protein, the cells were harvested and dissolved in RIPA (Beyotime, Nanjing, China) buffer. The protein concentrations were determined by a BCA protein assay kit. Equal amounts of protein lysates (40 mg/lane) were loaded and resolved on 10% sodium-dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Sigma-Aldrich) and then were transferred onto nitrocellulose filters and probed with rabbit anti-Col2A1, Sox9, β-actin, histone 3, NFATc2 (1:900) (all from Santa Cruz Biotechnology), and p-NFATc2 (1:500) (Abcam, Cambridge, MA, USA) antibodies at 4 °C overnight. After incubation with a horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology), the blots were developed by enhanced chemiluminescence following the manufacturer's protocol and were visualized by exposure to a Fusion FX system (VilberLourmat, Marne-la-Vallee, France). The protein amounts in electrophoresis gels were analyzed with the Quantity One 4.6 analysis software (Bio-Rad Laboratories, Hercules, CA, USA). All solutions in this procedure contained a mixture of protease and phosphatase inhibitors.

Table 1 Primer used for qPCR

| Gene | Forward Primer | Reverse Primer | Anneal |
|------|----------------|----------------|--------|
| GAPDH | GCAAGTTCACGGCCAGCAG | GCCCAGTACCTCCACGACA | 60 °C |
| Col2A1 | GAGTGGAGAGGCGGAGACTACTG | CTCATGTTGCCAGAACTTCTCA | 60 °C |
| Sox9 | CCAGCAAGAAACAGCAGC | CTTGCACCGAGCTTCTGA | 60 °C |
| a3-nAChR | GTGGGATGACAGAAGACAG | AGGGCACGGTAGAAGCAGA | 60 °C |
| a4-nAChR | CACGTCCTCCTGTGCTCAATGT | CCTTTGTTGCAGATGTCCACT | 62 °C |
| a5-nAChR | GCTGGCTCTGCTTGTGCAGT | CGTATGTCAGCAAGCCGAT | 60 °C |
| a7-nAChR | ACAATACGCCCCAACGACCA | GGCGATTGTCGCCATCAGG | 60 °C |
| β2-nAChR | GGAGTGGAGAAATGACCGC | AGTCGTGCCTGCTGGTGGC | 60 °C |
| β4-nAChR | GATTCTCCCAAGCAGAACCTT | AAGCTGGAGATTGTGGTGA | 60 °C |

Abbreviations: PCR polymerase chain reaction, GAPDH glyceraldehyde phosphate dehydrogenase, Col2A1 α1 chain of type II collagen gene, Sox9 SRY-type high mobility group box9, nAChR nicotinic acetylcholine receptor
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChiP) assays were performed as previously described [29]. In brief, 6 × 10⁶ cells were fixed with 1% formaldehyde and quenched by glycine. The cells were washed three times with PBS and then harvested in ChIP lysis buffer (50 mM Tris-HCl, pH 8.0, 1% SDS and 5 mM EDTA, all from Sigma-Aldrich). DNA was sonicated to 400–600 bp before extensive centrifugation. Four volumes of ChIP dilution buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA and 1% Triton X-100, all from Sigma-Aldrich) were added to the supernatant. The resulting lysate was then incubated with protein G beads (GE Healthcare, Chicago, IL, USA) and H3K9 (Abcam), H3K14 (Abcam) antibodies at 4 °C overnight. The beads were washed vigorously with wash buffer (20 mM Tris-HCl pH 8.0, 1% SDS and 5 mM EDTA, all from Sigma-Aldrich) with proteinase inhibitors. The supernatant was then incubated with protein G beads (GE Healthcare, Chicago, IL, USA) and H3K9 (Abcam), H3K14 (Abcam) antibodies at 4 °C overnight and DNA was extracted with a DNA purification kit (Tiangen Biotech, Beijing, China). The purified DNA was assayed by quantitative PCR assays were repeated at least three times. Data were expressed as a percentage of input DNA. The primer information is in Table 2.

Immunoprecipitation
Immunoprecipitation was performed following the method described in a previous study [30]. Cell lysates from BMSCs were prepared in NP40 lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP40, all from Sigma) or high-salt lysis buffer (20 mM HEPES pH 7.4, 10% glycerol, 0.35 M NaCl, 1 mM MgCl₂, 0.5% Triton X-100, 1 mM DTT, all from Sigma-Aldrich) with proteinase inhibitors. The supernatant was then incubated with protein G beads (GE Healthcare) and the NFATc2 antibody (Santa Cruz Biotechnology) at 4 °C for 4 h. Beads conjugated with the lysates and antibodies were collected by centrifugation and washed three times with lysis buffer. The final amount of wash buffer was aspirated and SDS loading buffer was added to the beads. The prepared proteins were resolved using 10% SDS-PAGE and then transferred to nitrocellulose membranes. Finally, the membranes were incubated with antibodies against HDAC1 (Santa Cruz Biotechnology) for 12 h. Chemiluminescence was detected using the above-mentioned ECL system.

Table 2 Primer used for ChiP

| Transcript | Sense primer | Antisense primer | Product | Annea |
|------------|--------------|-----------------|--------|------|
| Sox9(327~ 429) | GCTCGGAACTGCTCTGAAAC | GAACCCAGGGCTACTTGCA | 103 bp | 60 °C |
| Col2A1(413~ 546) | GCACCTAGGGCGATCTGTTA | GAGCTGCTGGCTGACTTT | 134 bp | 60 °C |

Abbreviations: ChiP chromatin immunoprecipitation, Col2A1 a1 chain of type II collagen gene, Sox9 SRY-type high mobility group box 9

Statistical analysis
SPSS 17 (SPSS Science, Chicago, IL, USA) was used for data analysis. Quantitative data were expressed as the means ± SEM. Data of two groups were evaluated with independent sample Student’s t tests, and the comparisons among more than two groups were performed using one-way ANOVA followed by Dunnett’s post hoc Student’s t tests. The macroscopic and histological score was evaluated using the Mann–Whitney U test. Statistical significance was defined as P < 0.05.

Results
Nicotine had an adverse effect on chondrogenic repair of BMSCs in cartilage defect
To evaluate the impact of nicotine on cartilage defect repair, we used a femoral trochlear cartilage defect rat model, which was repaired by BMSC transplantation. Nicotine was injected at 1.0 mg/kg twice per day (2.0 mg/kg/d). The effect of nicotine on cartilage repair was analyzed. At 12 weeks post-transplantation, no abnormal findings suggested rejection or infection, such as severe inflammation or extensive fibrosis, and no synovial edema was observed in either group. In the control group, the defects were covered with smooth regenerated tissues with surrounding cartilage, and the tissues were well integrated with the surrounding cartilage although there remained part of a depressed tissue with a demarcating border < 1 mm (Fig. 1a). Safranin O staining showed that the cartilage defect was filled to the full depth and smooth regenerated tissues with good column alignment, which were well integrated with both edges of normal cartilage, and the graft had a normal matrix-staining compared with adjacent cartilage. The cell morphology was similar to the native cartilage, which was round or ovoid shaped in neat rows and obvious lacuna (Fig. 1d). In the experimental group, part of the regenerated tissues had a fibrillated surface, most parts of the defects were filled with regenerated tissues level with the surrounding cartilage, little was clearly distinguishable from the normal cartilage, and part of the graft had a fibrillated surface (Fig. 1b). The marked reduced safranin-O staining was exhibited in regenerated tissues, which fully covered the defect. The cell morphology was almost the same as fibrocartilage, which showed an irregular arrangement and no lacuna (Fig. 1e). The macroscopic scores of the control group were much higher than those of the experimental group (Fig. 1c), and the microscopic scores in the control group were
much lower than the experimental group (Fig. 1f). The result suggested that the transplantation of BMSCs with alginate could effectively repair the cartilage defect as the regenerated tissue was almost the same as hyaline cartilage. Nicotine had an obvious adverse effect on cell morphology of the regenerated tissue and synthesis of cartilage matrix.

Nicotine inhibited cartilage repair by suppressing Sox9 expression
To explore the mechanism of nicotine's suppression on chondrogenic cartilage repair of the cartilage defect, we measured the expression of matrix and Sox9 in the regenerated tissues. Immunohistochemical staining of sections with Col2A1 and Sox9 antibodies showed the proteins in the regenerated tissue stained positive. The staining of Col2A1 was stronger in the control group than the experimental group (Fig. 2a and b), similar to Sox9 (Fig. 2d and e). The mean optical densities of Col2A1 and Sox9 were reduced in the experimental group (Fig. 2c and f). RNA was extracted from the regenerated tissues of both groups, and the mRNA expression of aggrecan, Col2A1, and Sox9 in the experimental group were decreased (Fig. 2g), which was consistent with protein expression by immunostaining. These findings demonstrated that nicotine inhibited the expression of Col2A1 and Sox9 in regenerated tissue. As Sox9 is the upstream cellular signal of Col2A1, we concluded that nicotine decreased the expression of Col2A1 by suppressing Sox9 and then negatively influenced the cartilage defect repair.

Nicotine increased the intracellular Ca\(^2+\) and phosphatase activity of calcineurin through α7-nAChR
To investigate the mechanism of nicotine's suppression on chondrogenic differentiation of BMSCs, 0.1 to 100μM nicotine treatment was used in BMSCs. The intracellular signals were tested to verify whether the Ca\(^2+\)/CaN/NFAT pathway mediated the inhibitory effect of nicotine. We performed a calcium imaging assay for P3 BMSCs. The results showed that the fluorescence intensity of BMSCs increased 5–10 min after administering nicotine and that the slope of the fluorescent intensity curve was different, which grew gradually with increasing nicotine exposure. Nicotine elicited an increase of intracellular calcium in a concentration-dependent manner (Fig. 3a). The onset time of nicotine in our research was 5–10 min due to the process of nicotine's diffusion into BMSCs. Thus, we measured the phosphatase activity of calcineurin in 0.5 h after nicotine stimulus and found that the enzyme activity of calcineurin was also increased in a concentration-dependent manner (Fig. 3b).

Because nAChR in MSCs has a large Ca\(^2+\) permeability and induces elevated intracellular free calcium by releasing intracellular calcium stores, we verified whether nicotine exerted its effect through nAChR in BMSCs. Total RNA and proteins were extracted from BMSCs, and an examination by RT-PCR and Western blotting showed that α7-nAChR was expressed in BMSCs (Fig. 3c). We found that 10μM methyllycaconitine (MLA), the specific antagonist of α7-nAChR, conversely eliminated the nicotine-induced calcium influx (Fig. 3d), implying that the effect of nicotine on BMSCs was fulfilled through α7-nAChR.

Fig. 1 Effects of nicotine on the repair of the cartilage defect with BMSCs transplantation in a rat model after 12 weeks. a and b Macroscopic observation of cartilage repair (×100). c Macroscopic scores of cartilage repair. d and e Safranin-O and fast green staining of cartilage repair (×100). f Histological scores of cartilage repair. Data represent mean ± SD (n = 8). *p < 0.05. Scale bar = 200 μm. BMSCs bone marrow mesenchymal stem cells.
Nicotine suppressed Sox9 by activating the Ca\(^{2+}\)/calcineurin/NFATc2 signaling pathway through α7-nAChR

Nicotine exposure increased the concentration of Ca\(^{2+}\) and calcineurin phosphatase activity increased over a short period. To detect the molecular mechanism of nicotine’s negative effect, BMSCs were treated with nicotine at different times to detect the expression change of Sox9. The results showed that the mRNA expression of Sox9 decreased in 24 h after nicotine exposure (Fig. 4a-c), and the protein expression of Sox9 also declined (Fig. 4d and e). The NFAT protein has calcineurin binding sites in the regulatory domain and is regulated by Ca\(^{2+}\) and calmodulin-dependent serine phosphatase calcineurin [22]; therefore, we extracted the total protein, cytoplasmic proteins and nucleoproteins and found that although no significant changes were observed in the expression of NFATc2 of whole cells (Fig. 4f and g), the expression of nucleic NFATc2 protein was elevated (Fig. 4h and i) and the cytoplasm phosphorylated NFATc2 was reduced by nicotine (Fig. 4j and k), indicating that NFATc2 was rapidly dephosphorylated and localized to the nucleus following nicotine treatment and that the dephosphorylated NFATc2 remains in the nucleus in the continued presence of nicotine. To further verify the molecular mechanism of nicotine’s suppression of Sox9, we performed RNAi-mediated stable knockdown of Sox9 expression in cultured BMSCs. NFATc2 expression was significantly suppressed at both the mRNA and protein levels (Fig. 4l and m). The results showed that the expression of Sox9 had no change when 10 μM MLA and Si-NFATc2 were given 0.5 h before the nicotine exposure (Fig. 4n and o), implying that interventions aimed at α7-nAChR and NFATc2 could reverse nicotine’s suppressive effect on the expression of Sox9. Therefore, nicotine suppressed Sox9 by activating the Ca\(^{2+}\)/calcineurin/NFATc2 signaling pathway through α7-nAChR.

Nicotine decreased the histone acetylation on the promoter of Sox9 in BMSCs

Nicotine exposure resulted in the dephosphorylation and increased the nucleic translocation of NFATc2, and then NFATc2 could bind to a site downstream of the transcriptional start site of the target gene and play a role in the downregulation of gene expression [23]. Given the
finding that nicotine exposure resulted in a significant decrease of Sox9 expression, our investigation further focused on the histone acetylation of the Sox9 promoter. The result of ChIP analysis indicated that the binding of NFATc2 and HDAC1 on the Sox9 promoter was increased (Fig. 5c and d) and that H3K9ac and H3K14ac levels on the Sox9 promoter were reduced (Fig. 5a and b) while a decreased binding of Sox9 on Col2A1 was also observed (Fig. 5e). The above changes induced by nicotine were characterized in a concentration-dependent manner. Moreover, when treatment of 10 μM MLA or si-NFATc2 was performed before nicotine exposure, the levels of H3K9ac and H3K14ac were rescued to the level of untreated control (Fig. 5f and g), and the induced binding of Sox9 on Col2A1 was also reversed (Fig. 5h). Therefore, nicotine treatment resulted in dephosphorylation and increased nucleic translocation of NFATc2. Then, NFATc2 and HDAC1 bound on the Sox9 promoter reduced the levels of H3K9ac and H3K14ac on the Sox9 promoter and decreased Sox9 expression. Reduced binding of Sox9 with Col2A1 further decreased Col2A1 expression.

Nicotine increased the interaction of NFATc2 and HDAC1. HDACs participate in decreasing the histone acetylation level of gene promoters. The transcriptional activity of NFAT proteins can regulate gene expression negatively depending on which binding partners are involved. Nicotine exposure resulted in the binding of NFATc2 to Sox9 and decreasing H3K9ac and H3K14ac levels in the Sox9 promoter. To investigate the molecular mechanism of the nicotine-induced decreased level of H3K9ac and H3K14ac in the Sox9 promoter, we used immunoprecipitation to measure the interaction of NFATc2 and HDAC. The result showed that the interaction of NFATc2 with HDAC1 was enhanced in a concentration-dependent manner after nicotine exposure (Fig. 6a), and no significant change of interaction was observed when si-NFATc2 and MLA were used before nicotine treatment (Fig. 6b). These results implied that NFATc2 could bind to the Sox9 promoter and recruit HDAC1, which also binds to the Sox9 promoter to form the complex, and the latter could reduce H3K9ac and H3K14ac levels in the Sox9 promoter and decrease the expression of Sox9.

Discussion
In the present study, we first verified the adverse effect of nicotine on the chondrogenic repair function of BMSCs in rat articular cartilage defects and proposed that Sox9 plays a key role in this process. Based on our previous study, we further confirmed nicotine’s suppression of Col2A1 expression and chondrogenic differentiation of BMSCs, the mechanism of which may involve decreasing the histone acetylation of the Sox9 promoter region through activation of Ca²⁺/CaN/NFAT signaling.
Fig. 4 (See legend on next page.)
The altered gene expression and promoter acetylation patterns could be blocked by antagonism of α7-nAChR, indicating that the direct effect of nicotine is mediated by α7-nAChR. Therefore, nicotine could interfere with cartilage repair through suppressing Sox9 expression in chondrogenic differentiation of BMSCs.

Nicotine is a high-risk factor for many diseases and has negative effects on soft and bony tissue healing [11, 12], which can also influence the repair of cartilage defects and suppress the chondrogenic differentiation of BMSCs [13, 17]. However, the mechanism of nicotine’s adverse effect is still unclear. Previous researches had clarified the chondrogenic potential of MSCs involved in cartilage regeneration [28, 31]. Similarly, the regenerated tissue in our study could have been differentiated from BMSCs. In addition to their differentiation potential, the paracrine action of MSCs was also believed to contribute to their therapeutic effects [32, 33], unknown factors secreted from BMSCs may stimulate chondrogenic differentiation in the repair process. Thus, we believed the mechanism of cartilage repair in defect was associated with chondrogenic differentiation and the secretive action of BMSCs. Sox9 is a key transcriptional factor and Sox9 expression of BMSCs with stimulus of nicotine for 24 h. d and e Protein expression of Sox9 in BMSCs with stimulus of nicotine for 24 h. f and g Expression of NFATc2 in total protein with stimulus of nicotine for 24 h. h and i Expression of phosphorylated NFATc2 in the cytoplasm with stimulus of nicotine for 24 h. j and k Expression of NFATc2 in total protein with stimulus of nicotine for 24 h. l and m Effect of Si-NFATc2 on BMP2 expression in BMSCs.

Fig. 4 Effects of nicotine on Sox9 and NFATc2 expression in BMSCs. Assay was performed after 24 h of in vitro culture. a mRNA expression of Sox9 in BMSCs with stimulus of nicotine for 8 h. b mRNA expression of Sox9 in BMSCs with stimulus of nicotine for 16 h. c mRNA expression of Sox9 in BMSCs with stimulus of nicotine for 24 h. d and e Protein expression of Sox9 in BMSCs with stimulus of nicotine for 24 h. f and g Expression of NFATc2 in nucleoproteins with stimulus of nicotine for 24 h. h and i Expression of phosphorylated NFATc2 in the cytoplasm with stimulus of nicotine for 24 h. j and k Expression of NFATc2 in total protein with stimulus of nicotine for 24 h. l and m Effect of Si-NFATc2 on BMP2 expression in BMSCs.

Nicotine is a high-risk factor for many diseases and has negative effects on soft and bony tissue healing [11, 12], which can also influence the repair of cartilage defects and suppress the chondrogenic differentiation of BMSCs [13, 17]. However, the mechanism of nicotine’s adverse effect is still unclear. Previous researches had clarified the chondrogenic potential of MSCs involved in cartilage regeneration [28, 31]. Similarly, the regenerated tissue in our study could have been differentiated from BMSCs. In addition to their differentiation potential, the paracrine action of MSCs was also believed to contribute to their therapeutic effects [32, 33], unknown factors secreted from BMSCs may stimulate chondrogenic differentiation in the repair process. Thus, we believed the mechanism of cartilage repair in defect was associated with chondrogenic differentiation and the secretive action of BMSCs. Sox9 is a key transcriptional factor and Sox9 expression of BMSCs. We observed that nicotine could reduce the expression of Sox9 itself is mainly regulated by histone acetylation [20]. Histone acetylation is concentrated mainly on histone 3 and histone 4 [40], and H3K9 and H3K14 acetylation often co-occur at many gene regulatory elements and adjust the gene expression in stem cells [41]. Based on these data, we focused on nicotine’s regulation of H3K9 and H3K14 acetylation and recruit HDAC1 to decrease the histone acetylation of BMSCs. We observed that nicotine could reduce the expression of Sox9 through decreasing H3K9 and H3K14 acetylation of the Sox9 promoter region and finally suppress the chondrogenic differentiation potential of BMSCs. Our in vitro data are consistent with the in vivo results where nicotine directly decreased the expression of Sox9 through α7-nAChR by suppressing the histone acetylation of the Sox9 promoter during the process of BMSCs chondrogenic differentiation.

NFAT is a family of transcription factors critical in regulating early gene transcription in response to T cell receptor-mediated signals in lymphocytes [42]. NFATc2 is a repressor of chondrogenesis [21] and can induce gene silencing through interaction with HDAC [22]. Our study demonstrated that NFATc2 could bind with Sox9 and recruit HDAC1 to decrease the histone acetylation of the Sox9 promoter. Calcineurin (also called protein phosphatase 2B), the only serine/threonine protein phosphatase under the control of Ca^{2+}/calmodulin, plays a critical role in the coupling of Ca^{2+} signals to cellular responses [43]. Ca^{2+} is the upstream signaling molecule of calcineurin, and the increased Ca^{2+} can activate the
enzyme activity of calcineurin. The complex regulation of calcineurin can dephosphorylate phosphorylated serine/threonine proteins and initiate multiple pathways. NFATc2 is the downstream signal of calcineurin [44], and the response to an increase of intracellular Ca^{2+} is dependent upon the dephosphorylation of NFATc2 by...
calcineurin. The activated calcineurin controls the translocation of NFAT proteins from the cytoplasm to the nucleus and regulates the expression of target genes [23]. Neuronal nAChR is usually in excitable cells of the central nervous system and controls the influx and efflux of Na⁺, K⁺, and Ca²⁺ [45]. Recent studies found that nAChR was also in non-excitable cells outside the nervous system [24, 46], providing physiologic functions in these cells [47], in which Ca²⁺ plays an important role in a signaling cascade activated by nAChR. Stimulation of MSCs with nicotine induced increases of intracellular Ca²⁺ concentration and initiated the downstream pathway of cascade activation while MLA, which is the specific antagonist of α7-nAChR, could inhibit the calcium influx [48]. In the present study, we found that α7-nAChR was presented in BMSCs and a nicotine stimulus could increase intracellular Ca²⁺ and the enzyme activity of calcineurin of BMSCs. The expression of dephosphorylated NFATc2 in the cytoplasm decreased and NFATc2 in the nucleus increased. Therefore, nicotine could activate Ca²⁺/Calcineurin/NFAT signaling in BMSCs through α7-nAChR, resulting in recruitment of HDAC1, which decreased histone acetylation of the Sox9 promoter region and finally inhibited BMSC chondrogenic differentiation.

The dose of nicotine exposure in our study is 2 mg/kg/d, which is consistent with previous animal studies [49, 50]. According to a previous investigation, an average tobacco rod contains 10–14 mg of nicotine, and on average, approximately 1.5 mg of nicotine is absorbed systemically during smoking [51]. Based on the dose–conversion correlation between humans and rats (human: rats = 1: 6.17) [52], the dose of nicotine exposure in the present study is equivalent to the nicotine exposure in an adult weighing approximately 70 kg smoking 2.3 cigarettes per day (calculated as follows: 2 mg/kg/d ÷ 6.17 × 70 kg ÷ 10 mg/cigarette = 2.3 cigarettes/d). The definition of nicotine dependence is the equivalent of more than ten cigarettes per day, and each cigarette contains at least 0.5 mg nicotine [53]. The dose of nicotine in our study was lower than the actual exposure of nicotine dependence in daily life. The present results showed the obvious impact of nicotine on cartilage repair. Thus, nicotine’s adverse effect with nicotine dependence would be more serious. The concentration of nicotine (0.01–10 μM) used in our chondrogenic differentiation model is consistent with those often used in pluripotent stem cell studies [54, 55]. The blood concentrations of nicotine during daily smoking are 0.06 μM to 0.23 μM [56], the initial concentration of nicotine in our study was 0.1 μM, which was within the range of a daily smoker’s nicotine blood concentration and could suppress the chondrogenic differentiation of BMSCs. Based on the principle of toxicology, we set a concentration gradient from 0.1 to 100 μM. The result showed that nicotinic suppression on BMSC chondrogenic differentiation has concentration-dependent characteristics. Although the largest nicotine exposure used in the present study was 100 μM, which was significantly higher than the plasma nicotine level of nicotine dependence, the result was the most obvious and the reversing experiment verified the key point of the molecular mechanism in this concentration, which is also helpful in clarifying the molecular mechanism.

Conclusions
In this study, we showed that nicotine at a dose under the actual exposure of nicotine dependence in daily life had an adverse effect on the chondrogenic repair of BMSCs in cartilage defects and that nicotine suppressed BMSC chondrogenic differentiation via the activation Ca²⁺/Calcineurin/NFATc2 signaling, which decreased the histone acetylation of the Sox9 promoter region. The
current study offers insight into the risk assessment of cartilage defect repair in a nicotine exposure population, advising individuals to avoid the negative impact of nicotine on BMSC cartilage repair to achieve high-quality repair of cartilage tissue.

Additional file

Additional file 1: Macroscopic observation of cartilage defect with no treatment and alginate transplantation in a rat model after 12 weeks. a Cartilage defect with no treatment. b Cartilage defect with alginate only. (DOCX 413 kb)

Abbreviations

BMSCs: Bone marrow mesenchymal stem cells; CaN: Calcineurin; ChIP: Chromatin immunoprecipitation; Col2A1: α1 chain of type II collagen; DMEM: Dulbecco’s modified Eagle’s medium; EDTA: Ethylenediaminetetraacetic acid; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; HDAC: Histone deacetylase; ITS: Insulin, transferrin and selenious; MALA: Methylallylalcoholine; MSCs: Mesenchymal stem cells; nAChR: Nicotinic acetylcholine receptor; NFATC2: Nuclear factor of activated T cell 2; PNPP: P-nitrophenyl phosphate; qRT-PCR: Quantitative real-time polymerase chain reaction; RT-PCR: Polymerase chain reaction; SDS-PAGE: Sodium-dodecyl sulfate-polyacrylamide gel electrophoresis; Sox9: SRY-type highmobility group box 9; TGF-β1: Transforming growth factor-β1

Acknowledgements

The authors thank the staff of the Center for Animal Experiment of Wuhan University.

Funding

This work was supported by the National Natural Science Foundation of China (Nos. 81371940, 81220108026 and 81702159) and Hubei Province health and family planning scientific research project (Nos. WJ2017Q012).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

LBC contributed to conception and design, analysis and interpretation of data, drafting the manuscript and revising the manuscript; HW contributed to conception and design, analysis and interpretation of data, drafting the manuscript and revising the manuscript; KT contributed to acquisition of data, analysis and interpretation of data, and drafting the manuscript; MW contributed to acquisition of data and drafting the manuscript; YD contributed to acquisition of data, YYD contributed to acquisition of data, DX contributed to analysis and interpretation of data. All authors read and approved the final manuscript.

Ethics approval

All animal experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals from the National Research Council of the United States National Academies, and approved by the Committee on the Ethics of Animal Experiments of the Wuhan University School of Medicine.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1 Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, People’s Republic of China. 2 Department of Pharmacology, Basic Medical School of Wuhan University, Wuhan 430071, People’s Republic of China. 3 Department of Biochemistry and Molecular Biology, College of Life Sciences, Wuhan University, Wuhan 430071, People’s Republic of China. 4 Hubei Provincial Key Laboratory of Developmentally Originated Diseases, 185 Donghu Road, Wuchang District, Wuhan 430071, People’s Republic of China.

Received: 27 December 2017 Revised: 2 March 2018 Accepted: 21 March 2018 Published online: 10 April 2018

References

1. Cohen NP, Foster RJ, Mow VC. Composition and dynamics of articular cartilage: structure, function, and maintaining healthy state. J Orthop Sports Phys Ther. 1998;28:203–15.
2. Vinatier C, Bouffé C, Merceron C, Gordeladze J, Brondello JM, Jorgensen C, et al. Cartilage tissue engineering: Towards a biomaterial-assisted mesenchymal stem cell therapy. Curr Stem Cell Res Ther. 2009;4:318–29.
3. Wdowochowski W, Wdowochowski J, Traska T. Articular cartilage defects: study of 25,124 knee arthroscopies. Knee. 2007;14:177–82.
4. Caplan AI. The mesengetic process. Clin Plast Surg. 1994;21:429–35.
5. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.
6. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoned a M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthr Cartil. 2002;10:199–206.
7. Filardo G, Madhy R, Jelic M, Roffi A, Cucchiari M, Kon E. Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics. Knee Surg Sports Traumatol Arthrosc. 2013;21:1717–29.
8. Halam AM, Singery AA, Saboy D, Atta HM, Rashed LA, Chu CR, et al. The clinical use of human culture-expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the Treatment of articular cartilage defects: a pilot study and preliminary results. Cartilage. 2010;1:253–61.
9. Wakitani S, Navata M, Temsho K, Okabe T, Machida H, Ogushi H. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J Tissue Eng Regen Med. 2007;1:74–9.
10. Johnson K, Zhu S, Tremblay MS, Payette JN, Wang J, Bouchez LC, et al. A stem cell-based approach to cartilage repair. Science. 2012;336(6082):717–21.
11. Triphagen N, Wyatt TA, Kharbanda K, Simet Chadwick S, Kolliputi N, Allen-Gipson DS. Cigarette smoke impairs A2A adenosine receptor mediated wound repair through up-regulation of duox-1 expression. Sci Rep. 2017;7:44405.
12. Santiago HA, Zanamori A, Sousa NMD, Volpon JB. Exposure to secondhand smoke impairs fracture healing in rats. Clin Orthop Relat Res. 2017;475(8):904–10.
13. Niemeyer P, Salzman GM, Hirschmüller A, Südkamp NP. Factors that influence clinical outcome following autologous chondrocyte implantation for cartilage defects of the knee. Z Orthop Unfall. 2012;150:83–4.
14. Tie K, Zhang X, Tan Y, Deng Y, Li J, Li Q, et al. Intratissue low-functional programming of IGF1 by prenatal nicotine exposure mediates the susceptibility to osteoarthritis in female adult rat offspring. FASEB J. 2016;30:785–97.
15. Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 2002;16:2801–28.
16. Lee KB, Wang VT, Chan YH, Hui JH. A novel, minimally-invasive technique of cartilage repair in the human knee using arthroscopic microfracture and injection of mesenchymal stem cells and hyaluronic acid-a prospective comparative study of safety and short-term efficacy. Ann Acad Med Singapore. 2012;41:511–7.
17. Deng Y, Li TQ, Yan YE, Magdalou J, Wang H, Chen LB. Effect of nicotine on chondrogenic differentiation of rat bone marrow mesenchymal stem cells in alginate bead culture. Biomed Mater Eng. 2012;22:281–7.
18. Hardingham TE, Oldershaw RA, Tew SR. Cartilage, SDX9 and Notch signals in chondrogenesis. J Anat. 2006;209:669–80.
19. Furumatsu T, Tsuda M, Taniguchi N, Tajima Y, Asahara H. Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem. 2005;280:3843–50.

20. Furumatsu T, Asahara H. Histone acetylation influences the activity of Sox9-related transcriptional complex. Acta Med Okayama. 2010;64:351–7.

21. Ranger AM, Gerstenfeld LC, Wang J, Kon T, Bae H, Gaivawale EM, et al. The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis. J Exp Med. 2000;191:9–22.

22. Im SH, Rao A. Activation and deactivation of gene expression by Ca^2+/*calcineurin- NFAT –mediated signaling. Mol Cells. 2004;18:1–9.

23. Baksh S, Widdlund HR, Frazer-Abel AA, Du J, Fosmire S, Fisher DE, et al. NFATc2-mediated repression of cyclindependent kinase 4 expression. Mol Cell. 2002;10:1071–81.

24. Hoogduijn MJ, Rao A. Activation and deactivation of gene expression by Ca^2+/*calcineurin- NFAT –mediated signaling. Mol Cells. 2004;18:1–9.

25. Chung JY, Song M, Ha CW, Kim JA, Lee CH, Park YB. Comparison of articular thickness articular cartilage defects in human patellae: two case reports. Cell Transplant. 2004;13:595–600.

26. Djouad F, Bouffé C, Ghanam S, Noel D, Jorgensen C. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol. 2009;5:392–9.

27. Caplan AI, Dennis JE. Mesenchymal stem cell-based repair of cartilage defects through soft tissue transfer. J Orthop Res. 1992;10:245–56.

28. Wang PF, Lee JS, Martin-Brown S, Florens L, Washburn M, et al. The promotion of cartilage repair with different hydrogel-human umbilical cord blood-derived mesenchymal stem cell composites in a rat model. Stem Cell Res Ther. 2014;5:39.

29. Henry SP, Liang S, Akdemir KC, de Crombrugghe B. The postnatal role of human Set1/COMPASS. Mol Cell Biol. 2008;28:7337–44.

30. Su SK, Li CY, Lei PJ, Wang X, Zhao QY, Cai Y, et al. H3K14ac marks a subset of inactive inducible promoters in mouse embryonic stem cells. BMC Genomics. 2012;13:424.

31. Klee CB, Ren H, Wang X. Regulation of the calmodulin stimulated protein phosphatase, calcineurin. J Biol Chem. 1998;273:13367–70.

32. Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. Sox9 is required for cartilage formation through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem. 2005;280:3843–50.

33. Caplan AI, Dennis JE. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol. 2009;5:392–9.

34. Caplan AI, Dennis JE. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol. 2009;5:392–9.

35. Akiyama H. Control of chondrogenesis by the transcription factor Sox9. Mod Mol Cell Biol. 2006;24:1076–84.

36. Henry SP, Liang S, Akdemir KC, de Crombrugghe B. The postnatal role of human Set1/COMPASS. Mol Cell Biol. 2008;28:7337–44.

37. Cao L, Yang F, Liu G, Yu D, Li H, Fan Q, et al. Molecular regulation of H3K4 trimethylation by Wdr82, a component of human Set1/COMPASS. Mol Cell Biol. 2008;28:7337–44.

38. Su SK, Li CY, Lei PJ, Wang X, Zhao QY, Cai Y, et al. The EZH1 human Set1/COMPASS. Mol Cell Biol. 2008;28:7337–44.

39. Jing YF. Histone deacetylase inhibitors, anticancenous mechanism and function. Annu Rev Immunol. 1997;15:707–47.

40. Wade PA, Pruss D, Wolffe AP. Histone acetylation: chromatin in action. Trends Biochem Sci. 1997;22:128–32.

41. Karmodiya K, Krebs AR, Oulad-Abdelghani M, Kimura H, Tora L. H3K9 and H3K14 acetylation co-occur at many gene regulatory elements, while H3K14ac marks a subset of inactive inducible promoters in mouse embryonic stem cells. BMC Genomics. 2012;13:424.

42. Hodge M, Ranger A, Charles de la Brousse F, Hoey T, Grudzy M, Glimcher L. Hyperproliferation and dysregulation of IL-4 expression in NFATp-deficient mice. Immunity. 1996;4:397–406.

43. Clark CB, Ren H, Wang X. Regulation of the calmodulin stimulated protein phosphatase, calcineurin. J Biol Chem. 1998;273:13367–70.

44. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997;15:707–47.

45. Utwin N. Acetylcholine receptor channel imaged in the open state. Nature 1995;373:37–43.

46. Kawakita A, Sato K, Makino H, Ikegami H, Takayama S, Toyama Y, et al. Nicotine acts on growth plate chondrocytes to delay skeletal growth through the alpha7 neuronal nicotinic acetylcholine receptor. PLoS One. 2008;3:e3945.

47. Sharma G, Vijayaraghavan S. Nicotinic receptor signaling in nonexcitable cells. J Neurobiol. 2002;53:234–38.

48. Blank U, Ruckes C, Claus W, Weber WM. Effects of nicotine on human nasal epithelium: evidence for nicotinic receptors in non-excitable cells. Pflugers Arch. 1997;434:581–6.

49. Costa LA, Jardim Pdos R, Macedo PH, Amaral Vda F, Silva AL, Barbosa CA. Evaluation of the abdominal wall cicatization of rabbits exposed to nicotine and undergone abdominoplasty using nylon thread or cyanoacrylate. Acta Cir. Bras. 2012;27:861–5.

50. Forrest CR, Pang CY, Lindsay WK. Dose and time effects of nicotine treatment on the capillary blood flow and viability of random pattern skin flaps in the rats. Br J Plast Surg. 1987;40:295–9.

51. Benowitz NL, Jacob P 3rd. Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther. 1984;35:499–504.

52. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659–61.

53. Schoberberger R, Kunze U, Schmeiser-Rieder A. Diagnosis and therapy of nicotine dependence. Versicherungsmedizin. 1997;49:25–9.

54. Liszewski W, Rittner C, Aurigui J, Wong SS, Hussan N, Krueger W, et al. Developmental effects of tobacco smoke exposure during human embryonic stem cell differentiation are mediated through the transforming growth factor-beta superfamily member. Nodal Differ. 2012;8:169–78.

55. Yu J, Huang NF, Wilson KD, Velotta JB, Huang M, Li Z, et al. nAChRs mediate human embryonic stem cell-derived endothelial cells proliferation, apoptosis, and angiogenesis. PLoS One. 2009;4:e7040.

56. Schneider NG, Olimstead RE, Franzon MA, Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet. 2001;40:661–9.

Submit your next manuscript to BioMed Central and we will help you at every step:

• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit